The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
Open accessAbstract
BACKGROUND: In the Survival and Ventricular Enlargement (SAVE) trial, recurrent myocardial infarction (MI) was the most important predictor of a poor outcome and conferred a sevenfold increase in risk of death. The purpose of this study was to determine the predictors of recurrent MI in study participants and to examine the influence of the angiotensin-converting enzyme inhibitor captopril on this and other myocardial ischemic events. METHODS AND RESULTS: The 2231 patients had survived the acute phase of MI (3 to 16 days) and had a radionuclide ventricular ejection fraction < or = 40%. Patients were randomly assigned to receive double-blind treatment with either placebo or captopril and were followed for an average of 42 months. The influence of captopril on recurrent MI, cardiac revascularization procedures, and hospitalization with unstable angina was examined. The likelihood of recurrent MI was greater in patients with an MI or functional disability before the index infarction and higher systolic pressure (all P < .001) but was not influenced by baseline left ventricular ejection fraction. Therapy with captopril reduced the risk of development of recurrent MI by 25% (95% confidence intervals, 5% to 40%; P = .015) and the risk of death after recurrent MI by 32% (95% confidence intervals, 4% to 51%; P = .029). Captopril-assigned patients were also less likely to require cardiac revascularization procedures (P = .010), but hospitalization for unstable angina was unaltered. When all three of these major coronary ischemic events were considered together, captopril therapy reduced the risk (14% risk reduction; 95% confidence intervals, 0% to 26%; P = .047). CONCLUSIONS: In post-MI patients with asymptomatic left ventricular dysfunction, long-term administration of captopril reduced recurrence of MI and the need for cardiac revascularization but had no influence on the rate of hospitalization with a discharge diagnosis of unstable angina. The finding that the recurrence of MI was independent of left ventricular ejection fraction suggests that captopril could be useful in preventing recurrent MI in patients with more preserved left ventricular function. The need for cardiac revascularization was reduced in patients receiving long-term captopril therapy, suggesting either an anti-ischemic effect or the ability of the angiotensin-converting enzyme inhibitor to modify the atherosclerotic process in survivors of MI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Self-citationJulian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · The Lancet · Cited by 1,860
Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury
Powell, J. S., Clozel, J.-P., Müller, R. K. M., Kuhn, H., Hefti, F., Hosang, M., & Baumgartner, H. R. (1989) · Science · doi:10.1126/science.2526370 · Cited by 1,052
Plasminogen activator inhibitors
Sprengers, E., & Kluft, C. (1987) · Blood · doi:10.1182/blood.v69.2.381.381 · Cited by 1,009
Swedberg, K., Held, P., Kjekshus, J., Rasmussen, K., Rydén, L., & Wedel, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271002 · Cited by 964
Alderman, M. H., Madhavan, S., Ooi, W. L., Cohen, H., Sealey, J. E., & Laragh, J. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104183241605 · Cited by 730
Yusuf, S., Pepine, C. J., Garces, C., Pouleur, H., Rousseau, M., Salem, D., Kostis, J., Benedict, C., Bourassa, M., & Pitt, B. (1992) · The Lancet · doi:10.1016/0140-6736(92)92889-n · Cited by 666
Prognosis after initial myocardial infarction: The Framingham study
Kannel, W. B., Sorlie, P., & Mcnamara, P. M. (1979) · The American Journal of Cardiology · doi:10.1016/0002-9149(79)90250-9 · Cited by 569
Diltiazem and Reinfarction in Patients with Non-Q-Wave Myocardial Infarction
Gibson, R. S., Boden, W. E., Theroux, P., Strauss, H. D., Pratt, C. M., Gheorghiade, M., Capone, R. J., Crawford, M. H., Schlant, R. C., Kleiger, R. E., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608143150704 · Cited by 537
Yusuf, S. (1988) · JAMA · doi:10.1001/jama.1988.03410140100032 · Cited by 491
Rouleau, J. L., Moye, L. A., Pfeffer, M. A., Arnold, J. M. O., Bernstein, V., Cuddy, T. E., Dagenais, G. R., Geltman, E. M., Goldman, S., Gordon, D., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303183281108 · Cited by 308
Self-citationPrognosis and Management after a First Myocardial Infarction
Moss, A. J., & Benhorin, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003153221107 · Cited by 172
Plasma Renin Activity and Ischemic Heart Disease
Meade, T. W., Cooper, J. A., & Peart, W. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308263290905 · Cited by 102
Rationale, design and baseline characteristics of the survival and ventricular enlargement trial
Moyé, L. A., Pfeffer, M. A., Braunwald, E., & The SAVE Investigators (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90263-k · Cited by 65
Self-citationDeaths and Non‐fatal Reinfarctions during Two Years' Follow‐up after Myocardial Infarction
VEDIN, A., Wilhelmsson, C., Elmfeldt, D., Säve-Söderbergh, J., Tibblin, G., & Wilhelmsen, L. (1975) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1975.tb19557.x · Cited by 63
Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction.
Søgaard, P., Gøtzsche, C.-O., Ravkilde, J., & Thygesen, K. A. (1993) · Circulation · doi:10.1161/01.cir.87.4.1093 · Cited by 59
Prognostic significance of nonfatal myocardial reinfarction
Benhorin, J., Moss, A. J., & Oakes, D. (1990) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)80043-9 · Cited by 56
Cited by
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Metadata
- Authors
- Rutherford, J. D., Pfeffer, M. A., Moyé, L. A., Davis, B. R., Flaker, G. C., Kowey, P. R., Lamas, G. A., Miller, H. S., Packer, M., & Rouleau, J. L.
- Venue
- Circulation
- Published
- 1994-10
- Volume
- 90
- Issue
- 4
- Pages
- 1731-1738
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2078757161
- Cited by
- 331
- References
- 17
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.